Santhera Launches U.S. Expanded Access Program with Idebenone for Patients with Duchenne Muscular Dystrophy (DMD) - Seite 3
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of
orphan mitochondrial and neuromuscular diseases. Santhera's lead product Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for the treatment of
Leber's hereditary optic neuropathy (LHON). Santhera is currently conducting the Phase III SIDEROS trial with idebenone in patients with Duchenne muscular dystrophy (DMD) in respiratory function
decline and using concomitant glucocorticoids. In collaboration with the U.S. National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing idebenone in a third indication,
primary progressive multiple sclerosis (PPMS), and another product - omigapil - for congenital muscular dystrophy (CMD), both also areas of high unmet medical need. For further information, please
visit the Company's website www.santhera.com.
Raxone® is a trademark of Santhera Pharmaceuticals.
For further information please contact:
public-relations@santhera.com or
Eva Kalias, Vio Consult
Phone: +41 78 671 98 86
kalias@vioconsult.com
For Investors:
investor-relations@santhera.com or
Christoph Rentsch, Chief Financial Officer Hans
Vitzthum, LifeSci Advisors
Europe: +41 61 906 89
65
US: +1 212 915 2568
christoph.rentsch@santhera.com
hans@lifesciadvisors.com
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain
forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements,
particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
Lesen Sie auch
# # #
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Globenewswire
--- End of Message ---
Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Switzerland
ISIN: CH0027148649;